Kathleen M Scullion

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

Clinical Practice

Placebo Controlled

Long Noncoding Rna

Top Venues

Toxicological sciences : an official journal of the Society of Toxicology

This page only lists publications with an associated author ORCID identifier.

Publications

Kathleen M Scullion, Iain M MacIntyre, Sian Sloan-Dennison, Benjamin Clark, Paul Fineran, Joanne Mair, David Creasey, Cicely Rathmell, Karen Faulds, Duncan Graham, David John Webb, James W Dear
Cytokeratin-18 is a sensitive biomarker of alanine transaminase increase in a placebo-controlled, randomized, crossover trial of therapeutic paracetamol dosing (PATH-BP biomarker substudy). Toxicological sciences : an official journal of the Society of Toxicology 199 (2) (2024)
Kathleen M Scullion, Iain M MacIntyre, Sian Sloan-Dennison, Benjamin Clark, Paul Fineran, Joanne Mair, David Creasey, Cicely Rathmell, Karen Faulds, Duncan Graham, David John Webb, James W Dear
Cytokeratin-18 is a sensitive biomarker of alanine transaminase increase in a placebo-controlled, randomized, crossover trial of therapeutic paracetamol dosing (PATH-BP biomarker substudy). Toxicological sciences : an official journal of the Society of Toxicology 199 (2) (2024)
Kathleen M Scullion, Iain M MacIntyre, Sian Sloan-Dennison, Benjamin Clark, Paul Fineran, Joanne Mair, David Creasey, Cicely Rathmell, Karen Faulds, Duncan Graham, David John Webb, James W Dear
Cytokeratin-18 is a sensitive biomarker of alanine transaminase increase in a placebo-controlled, randomized, crossover trial of therapeutic paracetamol dosing (PATH-BP biomarker substudy). Toxicological sciences : an official journal of the Society of Toxicology 199 (2) (2024)
Kathleen M Scullion, Iain M MacIntyre, Sian Sloan-Dennison, Benjamin Clark, Paul Fineran, Joanne Mair, David Creasey, Cicely Rathmell, Karen Faulds, Duncan Graham, David John Webb, James W Dear
Cytokeratin-18 is a sensitive biomarker of alanine transaminase increase in a placebo-controlled, randomized, crossover trial of therapeutic paracetamol dosing (PATH-BP biomarker substudy). Toxicological sciences : an official journal of the Society of Toxicology 199 (2) (2024)